GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBPP.PFD) » Definitions » EV-to-EBITDA

Regen BioPharma (Regen BioPharma) EV-to-EBITDA : 0.00 (As of May. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Regen BioPharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Regen BioPharma's enterprise value is $0.00 Mil. Regen BioPharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.82 Mil. Therefore, Regen BioPharma's EV-to-EBITDA for today is 0.00.

The historical rank and industry rank for Regen BioPharma's EV-to-EBITDA or its related term are showing as below:

RGBPP.PFD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -66.62   Med: -0.98   Max: 37.61
Current: -4.12

During the past 11 years, the highest EV-to-EBITDA of Regen BioPharma was 37.61. The lowest was -66.62. And the median was -0.98.

RGBPP.PFD's EV-to-EBITDA is ranked worse than
100% of 455 companies
in the Biotechnology industry
Industry Median: 10.21 vs RGBPP.PFD: -4.12

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), Regen BioPharma's stock price is $2.80. Regen BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.000. Therefore, Regen BioPharma's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Regen BioPharma EV-to-EBITDA Historical Data

The historical data trend for Regen BioPharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma EV-to-EBITDA Chart

Regen BioPharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.08 0.72 -21.15 12.81 5.73

Regen BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 4.75 5.73 -5.43 -4.50

Competitive Comparison of Regen BioPharma's EV-to-EBITDA

For the Biotechnology subindustry, Regen BioPharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's EV-to-EBITDA falls into.



Regen BioPharma EV-to-EBITDA Calculation

Regen BioPharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.000/-0.823
=0.00

Regen BioPharma's current Enterprise Value is $0.00 Mil.
Regen BioPharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regen BioPharma  (OTCPK:RGBPP.PFD) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Regen BioPharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.80/0.000
=N/A

Regen BioPharma's share price for today is $2.80.
Regen BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Regen BioPharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Regen BioPharma (Regen BioPharma) Business Description

Traded in Other Exchanges
Address
4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.